📄 Direct examination of Dr. Robin Cotton (morning, part 3) — Thursday, May 11, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\11\DIRECT-EXAMINATION-OF-DR-ROBIN.DOC
TRIAL
▲ Day 72 of 167

Direct examination of Dr. Robin Cotton (morning, part 3)

Witness: Dr. Robin Cotton
Examiner: George Clarke
Called by: Prosecution • Date: Thursday, May 11, 1995 • Utterances: 219
Dr. Robin Cotton continues her direct examination by prosecutor George Clarke, walking the jury through DNA results from the Bronco steering wheel, Rockingham driveway, Rockingham foyer, and the socks found at Simpson's residence. She explains how population frequency databases are used to estimate the rarity of DNA matches, covering both RFLP and PCR methodologies and the use of African American, Caucasian, and Hispanic reference populations.
1 (The following proceedings were held in open court, in the presence of the jury:)
2 THE COURT:

All right. Thank you, ladies and gentlemen. Please be seated. All right. Dr. Cotton, would you resume the witness stand, please. All right. The record should reflect that we have been rejoined by all the members of our jury panel. Mr. Clarke, you may proceed.

3 MR. CLARKE:

Thank you, your Honor.

4 MR. CLARKE:

Dr. Cotton, if we can, I would like just to go back to the results from the Bronco, that is, the steering wheel stain, item no. 29. You have described the fact that Mr. Simpson is not excluded or could have been a person who provided that blood stain; is that right?

5 DR. COTTON:

Yes, that's right.

6 MR. CLARKE:

And let's just start with DQ-Alpha. How do you know that? What about those results let's you know that?

7 DR. COTTON:

Item 29 has the following alleles: For DQ-Alpha it has a 1.1, a 1.2 and a 4. Mr. Simpson--

8 MR. CLARKE:

If I could, I'm sorry, I'm going to ask you if you would to point to the board as far as those markers that you just described for DQ-Alpha so that we can all see that.

9 THE COURT:

Steal my pointers?

10 DR. COTTON:

Here is one.

11 MR. CLARKE:

All right.

12 DR. COTTON:

Okay. Mr. Simpson is shown at the very top of the board and he has a 1.1 and a 1.2. The steering wheel, item no. 29 sample, has a 1.1 and a 1.2 and a 4, so two of the--two of the alleles or types that are found on the steering wheel are the same as Mr. Simpson's type, so he would be included based on the DQ-Alpha results as being a possible donor to the DNA taken from item 29.

13 MR. CLARKE:

Without getting into the individual types of the five polymarkers, was the same also true based on your typing results from that particular set of markers?

14 DR. COTTON:

Yes, it was.

15 MR. CLARKE:

Now, what about Nicole Brown? You described the fact that she also could be a donor of that stain.

16 DR. COTTON:

That's correct.

17 MR. CLARKE:

What do you base that conclusion on?

18 DR. COTTON:

Nicole Brown has a 1.1 type. She has two 1.1 alleles. There is a 1.1 in the steering wheel; and therefore, based on the DQ-Alpha results, she would also be included as a possible donor to that mixture of people.

19 MR. CLARKE:

What statement, if any, can you make that about DQ-Alpha 4 that is also a result obtained from this steering wheel?

20 DR. COTTON:

The DQ-Alpha 4 is shared with the allele 4 for Mr. Goldman, but his allele 1.3 isn't visible in the DQ-Alpha type from the steering wheel, so that 4 comes from someone, but we don't--we can't make any determination as to who.

21 (Discussion held off the record between the Deputy District Attorneys.)
22 MR. CLARKE:

As far as the results, and let's take the result you obtained in this case and let's take the steering wheel stain as an example--this is a picture, correct, of what you tested?

23 DR. COTTON:

Yes.

24 MR. CLARKE:

As far as when portions of a mixture may have been left on that steering wheel, can you scientifically state that they occurred at the same time?

KEY QUOTE
25 DR. COTTON:

No, absolutely not.

26 MR. CLARKE:

All right. If I could then, your Honor, I'm going to ask to be marked as People's exhibit 261 a further results board.

27 THE COURT:

All right.

28 (Brief pause.)
29 MR. CLARKE:

Which can be described, I believe, as the Rockingham residence and I believe that is right behind the current board.

30 THE COURT:

All right. 261.

31 (Brief pause.)
32 (Peo's 261 for id = posterboard)
33 THE COURT:

And we will need to raise that up.

34 (Discussion held off the record between the Deputy District Attorneys.)
35 MR. CLARKE:

Now, Dr. Cotton, referring you to this third results board labeled "Rockingham residence" and in particular to an item marked "no. 7, Rockingham driveway"--

36 DR. COTTON:

Yes.

37 MR. CLARKE:

--I believe you even discussed this item a little bit earlier this morning; is that right?

38 DR. COTTON:

Yes.

39 MR. CLARKE:

Did you in fact use that particular evidence stain from the Rockingham driveway and type it using the PCR technique?

40 DR. COTTON:

Yes, we did.

41 MR. CLARKE:

With what results?

42 DR. COTTON:

The results that we got, umm--we got DQ-Alpha types. We got polymarker results. There was no C dot again on this DQ-Alpha type, so although we saw some dots and we recorded those, there was no C dot for the DQ-Alpha. The polymarker results had the appropriate control dot and they were reported.

43 MR. CLARKE:

As far as these DQ-Alpha results on the Rockingham driveway, stain no. 7, did you say that you don't--well, let me rephrase that. You didn't see a C dot; is that right?

44 DR. COTTON:

That's right.

45 MR. CLARKE:

And as part of your protocol what effect does that have on your results?

46 DR. COTTON:

Well, it is the same thing that I said earlier this morning. That means the types that you have are types that are in that sample, but you cannot be guaranteed that there are not types that you are not seeing. That is, there may be types in the sample that you are not seeing in your DQ-Alpha results.

47 MR. CLARKE:

Was there anything about the types that you did see that excluded, for instance, Mr. Simpson?

48 DR. COTTON:

No, there were not.

49 MR. CLARKE:

All right. Your Honor, with the Court's permission I'm going to reveal the first magnetic cover.

50 THE COURT:

Proceed.

51 (Brief pause.)
52 MR. CLARKE:

And as far as these results, Dr. Cotton, can you make any statement about the three parties in this case, whether any of them can be included or excluded from these results?

53 DR. COTTON:

Based on the polymarker results, the--Mr. Simpson can be included and Nicole Brown and Ronald Goldman are excluded.

KEY QUOTE
54 (Discussion held off the record between the Deputy District Attorneys.)
55 MR. CLARKE:

And again, your Honor, with the Court's permission, I will remove that cover.

56 THE COURT:

Proceed.

57 (Brief pause.)
58 MR. NEUFELD:

Your Honor, for the record, it should be noted same objection I made before be a standing objection for similar situations.

59 THE COURT:

Noted. Thank you.

60 MR. NEUFELD:

Thank you.

61 THE COURT:

Proceed.

62 MR. CLARKE:

Let's turn to what's marked no. 12, the Rockingham foyer stain. Do you recall that?

63 DR. COTTON:

I do.

64 MR. CLARKE:

And you testified yesterday, as well as this morning, about the fact that that stain was tested using the RFLP method?

65 DR. COTTON:

That's right.

66 MR. CLARKE:

And there was a match obtained to Mr. Simpson; is that right?

67 DR. COTTON:

That's right.

68 MR. CLARKE:

At how many probes?

69 DR. COTTON:

Five.

70 MR. CLARKE:

Your Honor, I'm going to ask to remove that label.

71 THE COURT:

Proceed.

72 (Brief pause.)
73 MR. CLARKE:

And then let's turn to the PCR results on that particular stain. Did you obtain some?

74 DR. COTTON:

Yes, we did.

75 MR. CLARKE:

What were they?

76 DR. COTTON:

The results that we obtained on item 12 indicate that Mr. Simpson is a possible donor and that Nicole Brown and Ronald Goldman are excluded as possible donors.

77 MR. CLARKE:

Your Honor--your Honor, with the Court's permission again may I remove those labels?

78 THE COURT:

You may.

79 (Brief pause.)
80 MR. CLARKE:

Other than the fact that with regard to the Rockingham driveway stain no. 7 and the fact that no C dot was observed, are the types you actually detected the same in both no. 7 and no. 12, the Rockingham foyer stain, as far as the PCR results themselves?

81 DR. COTTON:

Yes. The types that we saw are the same.

82 MR. CLARKE:

And they both include Mr. Simpson but exclude both Ronald Goldman or Nicole Brown?

83 DR. COTTON:

Yes.

84 MR. CLARKE:

As far as no. 7 is concerned, the driveway stain, did you even attempt RFLP typing?

85 DR. COTTON:

I don't--no, we didn't.

86 MR. CLARKE:

Why not?

87 DR. COTTON:

The stain was too degraded--the DNA was too degraded.

KEY QUOTE
88 (Discussion held off the record between the Deputy District Attorneys.)
89 MR. CLARKE:

All right. As far as the particular items in this case, were you provided an unstained control from either of these stains?

90 DR. COTTON:

For 12 and 7?

91 MR. CLARKE:

And did you test those--I'm sorry, are you able to determine if you obtained controls for each of those items or one item or what?

92 DR. COTTON:

Umm, probably so, but are they in the set of controls that we obtained at the very end?

93 MR. CLARKE:

I believe so, if that will help you locate the document.

94 DR. COTTON:

It would.

95 (Brief pause.)
96 DR. COTTON:

Yes.

97 MR. CLARKE:

And was that both 7 and 12 or just one or the other?

98 DR. COTTON:

It was both 7 and 12.

99 MR. CLARKE:

And were these unstained substrate type controls that you were asked to test?

100 DR. COTTON:

Yes, they were.

101 MR. CLARKE:

Did you obtain any DNA results from either one of those controls?

102 DR. COTTON:

We did not obtain any results from either of those controls.

103 MR. CLARKE:

Now, taking you back to item no. 7, the Rockingham driveway stain, I believe you said the DNA was too degraded to use RFLP typing?

104 DR. COTTON:

Yes.

105 MR. CLARKE:

What does that mean?

106 DR. COTTON:

It means that the DNA had been broken up in a random manner by whatever affects it was exposed to and so it was--the pieces were basically too small to give an RFLP result.

107 MR. CLARKE:

And therefore you turned to PCR typing?

108 DR. COTTON:

PCR.

109 MR. CLARKE:

All right. With respect to these substrate controls, again what does that negative result mean to you as an analyst?

110 DR. COTTON:

It means that in--where--from wherever the substrate control was taken, presumably in a close--in an area close to the stain, that there was no DNA in that area.

111 MR. CLARKE:

All right. Your Honor, I would like to turn to one final results board. I believe that would be People's exhibit 262. I believe it can be described as the results board for the socks.

112 (Brief pause.)
113 THE COURT:

All right. 262, results board, socks.

114 (Peo's 262 for id = posterboard)
115 (Brief pause.)
116 MR. CLARKE:

Dr. Cotton, referring you to this new board that has been marked or will be marked that refers to People's 262, the Rockingham socks, you have already described RFLP testing that was conducted on stain material provided to you; is that correct?

117 DR. COTTON:

Yes.

118 MR. CLARKE:

And you described that material or that blood staining as matching Nicole Brown; is that right?

119 DR. COTTON:

That's correct.

120 MR. CLARKE:

The five probes?

121 DR. COTTON:

The five probes.

122 MR. CLARKE:

Did you also--and your Honor, may I remove the RFLP results cover?

123 THE COURT:

You may.

124 (Brief pause.)
125 MR. CLARKE:

Dr. Cotton, you described the fact that that five-probe match was with Nicole Brown; is that right?

126 DR. COTTON:

That's right.

127 MR. CLARKE:

May I also remove that cover, your Honor?

128 THE COURT:

You may.

129 (Brief pause.)
130 MR. CLARKE:

Now, turning your attention, Dr. Cotton, if I can, to PCR testing, was that also done on this DNA this blood-stained material from that sock?

131 DR. COTTON:

Yes, it was.

132 MR. CLARKE:

With what results?

133 DR. COTTON:

The results from the PCR testing, which is DQ-Alpha and polymarker, include Nicole Brown as being a donor and exclude Mr. Goldman and Mr. Simpson.

KEY QUOTE
134 MR. CLARKE:

All right. Your Honor, at this time may I remove the final cover?

135 THE COURT:

You may.

136 (Brief pause.)
137 MR. CLARKE:

Does that mean then, Dr. Cotton, that not only RFLP typing matched Nicole Brown, but so did six additional genetic markers using PCR?

KEY QUOTE
138 DR. COTTON:

It certainly does.

139 MR. CLARKE:

Now, Dr. Cotton, I would like to turn your attention to and return for a few moments to population frequency data. You use frequency data again in your description of the meaning of results; is that right?

140 DR. COTTON:

That's correct.

141 MR. CLARKE:

And the reason for that again is what?

142 DR. COTTON:

For any set of genetic markers, a particular combination might be more common or less common depending on the alleles, because not--some alleles are common and found in lots of people and some alleles are not very common and not found in very many people, so it is a way to say this is a common type or a rare type that we have identified in a particular sample.

143 MR. CLARKE:

Now, you described a couple days ago about determining this estimate, this means of providing some description about how rare or common types are that may be shared as being able to be used when more than one genetic marker is concerned; is that right?

144 DR. COTTON:

That's right.

145 MR. CLARKE:

How do you do that?

146 DR. COTTON:

Essentially you are saying how often do I see the set of characteristics in the first genetic marker I look at and then how often do I see the set of characteristics in the second genetic marker I've looked at. So the overall combination is that how often would I see the combination genetic characteristics from the first marker and the second marker would be the product of those two numbers, that is, you would multiply them together and that would give you the overall estimation of how often you would see the group of characteristics from two markers. If you added an additional marker, then you would multiply that in as well and so on.

147 MR. CLARKE:

Why is it appropriate or okay to do that, to provide this estimate?

148 DR. COTTON:

As long as the markers are inherited independently and are statistically independent of each other in their inher--that is, they need to be on separate chromosomes, but also people would ask are they statistically independent? As long as they are independent of one another, then the appropriate mathematical calculation is to multiply those individual frequencies of occurrence together to get the overall frequency of occurrence.

149 MR. CLARKE:

Now, with regard to this, and I believe you said different chromosomes; is that right?

150 DR. COTTON:

That's right.

151 MR. CLARKE:

Do you in fact use--and let's look at RFLP typing first. Do you use probes that have some different chromosomes or the same chromosomes?

152 DR. COTTON:

Of the five probes that we used, they are all on different chromosomes, with one exception, that is, two are on the same, although they are located at a considerable distance apart, which means that they also would be inherited independently, and the remainder are on four additional and different chromosomes.

153 MR. CLARKE:

That was going to be my next question. How can you use, for instance, these two probes or two genetic markers that you said were on the same chromosome?

154 DR. COTTON:

It is--the long explanation, which I won't try to give you, has to do with how DNA is distributed when eggs and sperm are created, that is, because they each have half. When two markers are relatively far apart on a chromosome, the chances of them being passed on to an offspring are equal. That is, it would be--they wouldn't tend to be passed along together and if something--I'm not doing this part very well. If two markers are close together on a chromosome, when that DNA goes into an egg or a sperm, they tend to go together. There is exchange of DNA between the chromosomes while eggs and sperm are being created, so that if two markers are far apart, they are not any more likely to go into the same egg or sperm as two markers that are on different chromosomes. That is the best I can do with--without giving a long biology lesson.

155 MR. CLARKE:

All right. With regard to these two markers that are on the same chromosome, have you done or have you established or shown to your satisfaction or other satisfaction that in fact they are not inherited together?

156 DR. COTTON:

The--the work was not done at Cellmark, the work was originally done by Alec Jeffries, and he established that they are in fact sufficiently far apart to be considered to be inherited independently.

157 MR. CLARKE:

Now, you have described this multiplication process, that is, the frequency at one marker, the frequency at the next marker and so forth. Is that any different than what has been used in these conventional serology cases about which we spoke for a number of years?

158 DR. COTTON:

No, it would be the same calculation as used in conventional serology.

159 MR. CLARKE:

Now, as far as calculating frequencies, did you calculate frequencies in this case based on your laboratory's results?

160 DR. COTTON:

Yes, we did.

161 MR. CLARKE:

And was that for the various samples that you have described over the last two days?

162 DR. COTTON:

Yes.

163 MR. CLARKE:

First of all, do you keep databases in your laboratory?

164 DR. COTTON:

Yes, we do.

165 MR. CLARKE:

What are those?

166 DR. COTTON:

It is basically a sample of a population of people from which you will derive your estimation of how often you would see a particular genetic characteristic.

167 MR. CLARKE:

And what purpose do you use these databases for?

168 DR. COTTON:

To ultimately assign a frequency to the genetic characteristics in a particular test and then assign an overall frequency for some combination of characteristics.

169 MR. CLARKE:

As far as these RFLP results in this case, and I believe you have described samples that match, for instance, Mr. Simpson; is that right?

170 DR. COTTON:

Yes.

171 MR. CLARKE:

As well as samples that match Nicole Brown?

172 DR. COTTON:

Yes.

173 MR. CLARKE:

Do you compare those set of characteristics or have you compared those set of characteristics to the number of individuals in your databases?

174 DR. COTTON:

Yes, we have.

175 MR. CLARKE:

Do either one of them match anyone in your databases?

176 DR. COTTON:

No, they do not.

177 MR. CLARKE:

Now, as far as your calculation--actually, let me ask another question. As far as your calculation of frequencies in this case, are those simply estimations of how rare these matching characteristics are?

178 DR. COTTON:

Yes.

179 MR. CLARKE:

What role, and I think you touched on this the day before yesterday, what role do major racial groups have in this frequency calculation process?

180 DR. COTTON:

For some genetic characteristics they can be more common--let me give a concrete example, maybe it will be a little bit easier. Let's just take DQ-Alpha, for example. And I'm making up these figures, since I don't remember the real ones. Let's say the type 1.1, 1.1. It could be very common in Caucasians and very rare in Hispanics or it could be very common in Caucasians and very rare in blacks, or the reverse, and so in order to give an appropriate range of how common or rare a set of characteristics is, it is usual to say this is the--this is the figure for how often you would see this in Caucasians, this is the figure for how often you would see this in African Americans and this is the figure how often you would see this in Hispanics. And if you had other racial databases at your disposal, you could go and do that for other groups as well.

181 MR. CLARKE:

Why don't you simply calculate an estimate of the frequency based on one group as opposed to another?

182 DR. COTTON:

Well, you could. It would sort of give you an overall kind of averaged figure, but it wouldn't give you the range of figures that using individual racial groups would, and therefore using individual racial groups is generally considered to be a more informative way of giving that number.

183 MR. CLARKE:

In the way of calculating these estimates, do you take any steps along the way--well, do you have to make decisions about kind of which way to do something when you calculate these frequencies? Does that make any sense?

184 DR. COTTON:

No.

185 MR. CLARKE:

Okay. Let me try that again then. Do you take any steps along the way to ensure that you are not making something sound, as far as a match, rarer than it really is?

186 DR. COTTON:

The particular steps that are taken--let me just refer to RFLP, because this is really where that becomes--that question becomes applicable. If you remember a couple days ago, I guess, I talked about--we sort of drew out a small database of five people and talked about looking at a window of sizes around a particular DNA fragment size, and it is that window that you are using to reflect the accuracy of your gel system and to not overestimate how rare a particular characteristic is.

187 MR. CLARKE:

As far as this calculation process itself, do you go through it, whether it is an RFLP type test or a PCR type test that is used?

188 DR. COTTON:

Yes.

189 MR. CLARKE:

Are there different--I think you said that there were a little bit different considerations in each of the two; is that right?

190 DR. COTTON:

In the PCR test, when you have, say, a 1.1 allele, you don't have any particular window you need to put around that. That is clearly defined as a 1.1; it is not close to a 1.1. It doesn't have the same features of creating a DNA fragment size where you know that that fragment size is also an estimation. So you have a 1.1 and you don't need to build a window around that, so you can go directly to your database and use the frequencies in the databases that you have available to you.

191 MR. CLARKE:

Now, as far as these various samples, do you calculate then this estimate or did you calculate this estimate based on different major racial groups?

192 DR. COTTON:

Yes, we did.

193 MR. CLARKE:

Can you describe what those racial groups are?

194 DR. COTTON:

We did the RFLP and the PCR estimates for African Americans, Caucasians and Hispanics.

195 MR. CLARKE:

Why do you use those groups?

196 DR. COTTON:

Those--those are the groups that we have data on at Cellmark, and in addition, the PCR data, some of that population data was compiled from other laboratories as well. The only other major racial group that we might use in the United States might be oriental, which would include Japanese and Chinese and Korean and so on. We do not at Cellmark have a population database that is currently in use for that racial group, so we aren't providing any statistical estimates for that group.

197 MR. CLARKE:

As far as these racial groups, and you have described that you have reported, for instance, in this case, results from three major groups?

198 DR. COTTON:

That's right.

199 MR. CLARKE:

What about the existence of other population groups around the world? There is more than three, obviously, and you have named a fourth.

200 DR. COTTON:

Is that a question?

201 MR. CLARKE:

I think that is a question, but I better make sure it is a question. You just named a fourth group, for instance, that you don't report results for?

202 DR. COTTON:

That's right.

203 MR. CLARKE:

And I believe you described the fact that that is because you don't have database material; is that right?

204 DR. COTTON:

That's right.

205 MR. CLARKE:

How do you know, when you report frequencies from these three groups, that you did perform that estimate process in this case, that somehow you are not overstating the rarity dramatically or significantly when other population groups may have in fact a more common set of these characteristics?

206 DR. COTTON:

Besides the population data that is available--available in our laboratory, there is an enormous amount of population data that has been produced by forensic laboratories all over the United States and all over Europe and a few laboratories elsewhere, including Australia and Japan. The system that we use that I discussed for this testing is not--I can't take our population data at Cellmark and compare it to population data that has been produced by the Federal Bureau of Investigation or the California Department of Justice, because we used a different restriction enzyme, and if you will just accept for the moment that that makes the DNA sizes a little bit different. However, the European community uses the same enzyme that we do, so there has been a lot of work mostly spearheaded through the Federal Bureau of Investigation to get all of the population data that has been obtained all together in one major volume. And when you look at all of this data together, what you see is that there are some differences in the populations, but they are not huge for RFLP loci, for those loci. This is not applicable--what I'm saying is not correct about the PCR loci. So I'm just talking about RFLP, so that you could go on and do more racial groups, but they would continue to produce numbers in the same range that you are getting with three or four, so it would be a more refined estimate, but it wouldn't really provide you with a huge amount of information that you aren't already getting with three.

207 MR. CLARKE:

Now, I believe you said that it does not apply to the PCR groups. What do you mean?

208 DR. COTTON:

The PCR locations that we've tested here do differ significantly from one racial group to the next, so if you did more than three groups, you might still see some differences, that is, you might get something that is more common than the three examples that we've provided or less common than the three examples we've provided. You could do that. We don't have that data at Cellmark. The data is available in the literature, but for convenience purposes we still in our reports for PCR provide the three groups that I've already talked about.

209 MR. CLARKE:

Now, as far as your reporting in this case, did you report estimated frequencies, in other words, estimates of how rare match characteristics are in the three major racial groups you have described?

210 DR. COTTON:

Yes, we did.

211 MR. CLARKE:

Now, as far as those estimates, can you or will you be able to tell us basically the range, that is, among those three groups as far as a set of characteristics to a sample, let's say, which is the most common group, that is the group with the most common estimate, versus the group with the least common or rarest estimate?

212 DR. COTTON:

Yes.

213 MR. CLARKE:

Would that then by doing so represent the range of rarity of matching characteristics?

214 MR. NEUFELD:

Objection, foundation for this witness.

215 THE COURT:

Overruled.

216 MR. CLARKE:

Now, your Honor, at this time I would like to return to the Bundy crime scene results board, exhibit 259.

217 THE COURT:

All right.

218 (Brief pause.)
219 THE COURT:

And let me see counsel at the side bar with the reporter, please.

Temperature

procedural

Key Quotes (5)

Dr. Robin Cotton
Based on the polymarker results, the--Mr. Simpson can be included and Nicole Brown and Ronald Goldman are excluded.
Directly ties Simpson's DNA to the Rockingham driveway blood stain while clearing the victims.
Dr. Robin Cotton
The results from the PCR testing, which is DQ-Alpha and polymarker, include Nicole Brown as being a donor and exclude Mr. Goldman and Mr. Simpson.
PCR results on the socks corroborate RFLP results, placing Nicole Brown's DNA on a sock found at Simpson's home.
Dr. Robin Cotton
Does that mean then, Dr. Cotton, that not only RFLP typing matched Nicole Brown, but so did six additional genetic markers using PCR? It certainly does.
Clarke elicits a succinct, powerful summary — eleven total genetic markers pointing to Nicole Brown's blood on the socks.
George Clarke
As far as when portions of a mixture may have been left on that steering wheel, can you scientifically state that they occurred at the same time?
Clarke preemptively neutralizes a potential defense argument by having Cotton acknowledge the science cannot determine timing of deposits.
Dr. Robin Cotton
The stain was too degraded--the DNA was too degraded.
Explains why RFLP was not attempted on the Rockingham driveway stain, establishing PCR as the appropriate method for that sample.

Evidence (5)

People's 261
Results posterboard for Rockingham residence DNA samples
introduced and discussed
People's 262
Results posterboard for Rockingham socks DNA samples
introduced and discussed
Item no. 29
Bronco steering wheel blood stain
discussed, DQ-Alpha and polymarker results reviewed
Item no. 7
Rockingham driveway blood stain
discussed, PCR results reviewed, RFLP not attempted due to degradation
Item no. 12
Rockingham foyer blood stain
discussed, both RFLP (5-probe match to Simpson) and PCR results reviewed

Notable Exchanges (3)

George ClarkeDr. Robin Cotton
Clarke walks Cotton through a detailed explanation of the product rule for multiplying allele frequencies across independent genetic markers, establishing the scientific basis for the rarity statistics to come.
strategic
George ClarkeDr. Robin Cotton
Cotton explains that PCR population frequencies can differ more significantly across racial groups than RFLP frequencies do, acknowledging a limitation in her three-group reporting while arguing it remains scientifically adequate.
revealing
Peter NeufeldLance A. Ito
Neufeld makes a standing objection to Clarke's practice of dramatically revealing covered sections of the results boards, which is noted for the record and allowed to stand going forward.
procedural

Light Moments (3)

Lance A. Ito
Judge Ito jokingly asks if Clarke is going to steal his pointer when Cotton needs one to indicate markers on the board.
Dr. Robin Cotton
Cotton responds 'No' when Clarke asks a confusingly worded question about frequency calculations, prompting Clarke to admit he needs to try again.
Dr. Robin Cotton
Clarke asks Cotton a rambling question and Cotton responds flatly 'Is that a question?' before Clarke self-corrects.

Objections

2 objections (0 sustained, 1 overruled)
Proceeding 6026 • 219 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 11, 1995 📄 Direct examination of Dr. Robi
MAY 11, 1995 KRT DvH TD